Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation

Shipounova, Irina N.; Petinati, Nataliya; Bigildeev, Alexey; Ni, Drize; Sorokina, Tamara; Кузьмина, Л А; Паровичникова, Е Н; Vg, Savchenko

doi:10.1080/10428194.2016.1187277

Cited by 11 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Fig. 1) These changes in proliferative ability of recipient stromal cells may occur due to the influence of malignant cell clones [18], or by previous rounds of chemotherapy [17]. One should discern between these potential causal factors.…”

Section: Resultsmentioning

confidence: 99%

Current methods and opportunities of next-generation sequencing (NGS) for HLA typing

Serov¹,

Barkhatov²,

Климов³

et al. 2016

CTT

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Current methods and opportunities of next-generation sequencing (NGS) for HLA typing

Serov¹,

Barkhatov²,

Климов³

et al. 2016

CTT

View full text Add to dashboard Cite

“…The total cell production of MSCs in these patients was significantly lower than that in donors (6.8 ± 1 times) and patients after a single bone marrow transplantation with normal restoration of donor hematopoiesis (3.8 ± 0.4 times) [ 4 ]. Administration of a small dose of donor MSCs was sufficient to restore donor hematopoiesis in these patients.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, in GF patients in a prolonged aplasia, hematopoietic microenvironment could be fatally damaged, and their stromal cells fail to support hematopoiesis [ 2 ]. After allo-HSCT, the stromal microenvironment suffers from the effects of chemotherapeutic drugs [ 3 , 4 ]. Not only does chemotherapy damage the bone marrow stroma but leukemia cells also adapt bone marrow niches to their own needs, altering the stromal microenvironment [ 4 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells

Petinati

Sats

et al. 2018

Stem Cells International

Self Cite

View full text Add to dashboard Cite

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac spine. For 8 patients with GF after allo-BMT, another hematopoietic stem cell transplantation with simultaneous implantation of MSCs from their respective donors into cancellous bone was performed. BM was aspirated from the iliac crest of these patients at 1-2, 4-5, and 9 months after the intraosseous injection of donor MSCs. Patients' MSCs were cultivated, and chimerism was determined. In 6 out of 8 patients, donor hematopoiesis was restored. Donor cells (9.4 ± 3.3%) were detected among MSCs. Thus, implanted MSCs remain localized at the site of administration and do not lose the ability to proliferate. These results suggest that MSCs could participate in the restoration of niches for donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection of the graft. Perhaps, intraosseous implantation of MSCs contributes to the success of the second transplantation of hematopoietic stem cells and patient survival.

show abstract

“…However, conditioning regimens can radically alter the BM microenvironment, damaging the stromal cells and impairing their ability to support hematopoiesis during recovery ( Banfi et al., 2001 ; Domenech et al., 1998 ). Significant changes in the gene expression and DNA methylation of multipotent mesenchymal stromal cells and HSPCs are detected in recipient BM up to 1 year after transplant ( Shipounova et al., 2017 ; Trino et al., 2019 ). The potential role for methylation in the transplant BM microenvironment is particularly compelling considering that DNMT3A mutations are frequently present in CHIP-associated DDL.…”

Section: Main Textmentioning

confidence: 99%

Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia

Burns

Kapur

2020

Stem Cell Reports

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a critical treatment modality for many hematological and non-hematological diseases that is being extended to treat older individuals. However, recent studies show that clonal hematopoiesis of indeterminate potential (CHIP), a common, asymptomatic condition characterized by the expansion of age-acquired somatic mutations in blood cell lineages, may be a risk factor for the development of donor-derived leukemia (DDL), unexplained cytopenias, and chronic graft-versus-host disease. CHIP may contribute to the pathogenesis of these significant transplant complications via various cell-autonomous and non-cell-autonomous mechanisms, and the clinical presentation of DDL may be broader than anticipated. A more comprehensive understanding of the contributions of CHIP to DDL may have important implications for the screening of donors and will improve the safety of HSCT. The objective of this review is to discuss studies linking DDL and CHIP and to explore potential mechanisms by which CHIP may contribute to DDL.

show abstract

Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation

Cited by 11 publications

References 46 publications

Current methods and opportunities of next-generation sequencing (NGS) for HLA typing

Current methods and opportunities of next-generation sequencing (NGS) for HLA typing

Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells

Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia

Contact Info

Product

Resources

About